文献综述(Review)

胰腺癌的分子靶向治疗研究进展

Published at: 2016年第25卷第9期

钟志惟 1 , 殷香保 1
1 南昌大学第二附属医院 肝胆胰外科,江西 南昌 330006
通讯作者 香保 殷 Email: yxb115@sina.com
DOI: 10.3978/j.issn.1005-6947.10.3978/j.issn.1005-6947.2016.09.022
基金:

摘要

胰腺癌是一种恶性程度最高的恶性肿瘤之一,预后极差,患者5年生存率低于5%。胰腺癌常规治疗的效果非常有限,是一个需要多学科综合治疗的恶性肿瘤。随着分子生物学研究的不断深入,表皮生长因子受体抑制剂等分子靶向药物在胰腺癌的治疗中表现出了巨大的潜力。笔者就分子靶向药物治疗胰腺癌的研究现状及进展做一综述。


Research progress in molecular targeted therapy for pancreatic cancer

Abstract

Pancreatic cancer is one of most malignant tumors with extremely poor prognosis, and the 5-year survival rate of the patients is below 5%. Conventional treatments produce very limited effects for pancreatic cancer, and it requires multidisciplinary approach and comprehensive management. With the deepening knowledge of molecular biology, molecular targeted drugs such as epidermal growth factor receptor inhibitors have shown impressive potential in treatment of pancreatic cancer. Here, the authors present the current status and progress in molecular targeted drug research for pancreatic cancer.


comments powered by Disqus

全文

引用

引用本文: 志惟 钟, 香保 殷. 胰腺癌的分子靶向治疗研究进展[J]. 中国普通外科杂志, 2016, 25(9): 1351-1356.
Cite this article as: ZHONG Zhiwei, YIN Xiangbao . Research progress in molecular targeted therapy for pancreatic cancer[J]. Chin J Gen Surg, 2016, 25(9): 1351-1356.